Shots:

• BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales
• In 2016- AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease
• BAN0805- a leading BioArctic’s Alpha-Synuclein Ab indicated for Parkinson Disease progression- while its IND is under process to onset its first clinical study in 2019

Ref: BioArctic| Image: AbbVie